Featuring Dov S. Zakheim, Senior Advisor, Center for Strategic and International Studies; Mackenzie Eaglen, Resident Fellow at the Marilyn Ware Center for Security Studies, American Enterprise Institute; Todd Harrison, Senior Fellow, Defense Budget Studies, Center for Strategic and Budgetary Assessments; and Christopher A. Preble, Vice President for Defense and Foreign Policy Studies, Cato Institute; moderated by Kate Brannen, Senior Reporter, Foreign Policy.
In the new issue of Regulation, economist Pierre Lemieux argues that the recent oil price decline is at least partly the result of increased supply from the extraction of shale oil. The increased supply allows the economy to produce more goods, which benefits some people, if not all of them. Thus, contrary to some commentary in the press, cheaper oil prices cannot harm the economy as a whole.
Two long wars, chronic deficits, the financial crisis, the costly drug war, the growth of executive power under Presidents Bush and Obama, and the revelations about NSA abuses, have given rise to a growing libertarian movement in our country – with a greater focus on individual liberty and less government power. David Boaz’s newly released The Libertarian Mind is a comprehensive guide to the history, philosophy, and growth of the libertarian movement, with incisive analyses of today’s most pressing issues and policies.
Featuring J. Scott Ballenger, Partner, Latham & Watkins; Ezekiel J. Emanuel, Chair, Department of Clinical Bioethics, National Institutes of Health; and Michael F. Cannon, Director of Health Policy Studies, Cato Institute.
In Abigail Alliance for Better Access to Developmental Drugs v. Eschenbach, terminally ill patients won an impressive victory before a panel of the U.S. Court of Appeals for the D.C. Circuit. That panel ruled that when the government prevents terminally ill patients from accessing experimental drug treatments, it violates those patients’ constitutionally protected right to save their own lives. On appeal, however, an en banc opinion from the D.C. Circuit overturned the panel opinion, setting the stage for an appeal to the Supreme Court. Please join Michael F. Cannon, the Cato Institute’s director of health policy studies; Scott Ballenger, lead counsel for the Abigail Alliance; and Ezekiel Emanuel, a leading critic of the Abigail Alliance’s case as they discuss the economics, ethics, and constitutionality of allowing the state to stand between dying patients and unproven therapies.